Top Page
Actinogen Medical
(Sydney:ACW)
Actinogen Medical (ACW) vs. iShares MSCI Australia ETF (EWA)
Actinogen Medical Business Overview & Revenue Model
Actinogen Medical Financial Statement Overview
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.49M | 5.49M | 9.93M | 4.89M | 3.64M | 1.98M |
| Gross Profit | 5.28M | 5.49M | 9.93M | 4.48M | 3.24M | 1.60M |
| EBITDA | -19.88M | -15.01M | -12.84M | -15.22M | -12.72M | -5.35M |
| Net Income | -17.91M | -14.73M | -13.04M | -10.75M | -9.50M | -3.92M |
Balance Sheet | ||||||
| Total Assets | 10.60M | 24.48M | 21.31M | 15.21M | 23.31M | 18.38M |
| Cash, Cash Equivalents and Short-Term Investments | 6.53M | 16.50M | 9.45M | 8.46M | 16.37M | 13.42M |
| Total Debt | 366.31K | 3.26M | 319.07K | 86.93K | 165.27K | 236.44K |
| Total Liabilities | 2.23M | 6.15M | 1.62M | 1.80M | 1.57M | 920.32K |
| Stockholders Equity | 8.37M | 18.34M | 19.70M | 13.41M | 21.74M | 17.46M |
Cash Flow | ||||||
| Free Cash Flow | -16.45M | -7.59M | -16.96M | -8.73M | -9.52M | -1.73M |
| Operating Cash Flow | -16.41M | -7.56M | -16.95M | -8.70M | -9.52M | -1.72M |
| Investing Cash Flow | -38.37K | -38.02K | -8.16K | -36.60K | -2.94K | -6.19K |
| Financing Cash Flow | 116.65K | 14.65M | 17.95M | 824.62K | 12.42M | 10.11M |
Actinogen Medical Technical Analysis
Actinogen Medical Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | AU$59.51M | 25.12 | 27.24% | 2.81% | 0.65% | -9.90% | |
55 Neutral | AU$74.43M | -1.38 | -100.67% | ― | 1114.27% | 85.66% | |
52 Neutral | AU$95.37M | -11.29 | -47.98% | ― | 700.00% | 26.88% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$69.40M | -6.60 | -49.72% | ― | ― | 10.78% | |
43 Neutral | AU$146.60M | -7.32 | -75.99% | ― | ― | 10.91% | |
41 Neutral | AU$87.00M | -6.67 | -42.68% | ― | ― | 63.46% |
Actinogen Medical Corporate Events
Actinogen Medical has completed a $16.8 million capital raise, including $4.8 million from a share purchase plan offered to existing shareholders on the same terms as a prior placement. The new funding lifts its pro forma 31 December 2025 cash balance to $29.5 million, significantly strengthening its financial position.
The company says the expanded cash runway will fund key 2026 initiatives, including starting an open-label extension study and completing non-clinical work, while supporting completion of its pivotal XanaMIA phase 2b/3 Alzheimer’s disease trial by November 2026. Management highlighted strong support from both institutional and retail investors, underlining market confidence in Xanamem’s prospects in the Alzheimer’s treatment landscape.
The most recent analyst rating on (AU:ACW) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.
Actinogen Medical Limited, an ASX-listed biotechnology company trading under the code ACW, has applied for quotation of additional ordinary fully paid shares. The move marginally increases its listed equity base, reflecting the conversion or exercise of existing options or other convertible securities.
The company will have 67,499 new ordinary fully paid shares quoted on the ASX from 26 February 2026. While small in scale, the issuance formalises earlier commitments embedded in its capital structure and modestly expands the free float available to investors.
The most recent analyst rating on (AU:ACW) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.
Actinogen Medical reported a modest decline in revenue from ordinary activities for the half year to 31 December 2025, with income of $232,920, largely from interest on cash and short-term deposits. The company remains in an investment phase, posting a net loss attributable to members of $11.35 million, a 39% increase on the prior corresponding period, predominantly driven by higher research and development spending.
No dividends were paid or declared for the period, and the company signalled it does not intend to pay dividends in the near term, underscoring its focus on funding ongoing development programs. Actinogen did not enter into any acquisitions, joint ventures or foreign operations during the half, and its reviewed interim financial report was signed off by an independent auditor without qualification, providing shareholders with assurance on the integrity of the reported results.
The most recent analyst rating on (AU:ACW) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.
Actinogen Medical has received a further A$1.87 million research and development tax incentive rebate from the Australian Tax Office, taking its total rebate for the 2025 financial year to A$7.36 million. The latest payment relates to overseas R&D expenditure that became eligible following approval under the Advanced Overseas Finding scheme.
The rebate strengthens Actinogen’s funding base as it nears key value inflection points in its Alzheimer’s disease program, including a phase 2b/3 trial of Xanamem that recently passed an independent safety and futility review. With topline results expected in November, the additional non-dilutive cash support is strategically important for sustaining clinical progress and may help the company maintain momentum in a competitive neurodegenerative drug development landscape.
The most recent analyst rating on (AU:ACW) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.
Actinogen Medical has launched a share purchase plan offering eligible shareholders in Australia, New Zealand and, in limited cases, the United States the chance to subscribe for up to $30,000 of new shares at $0.042 each without brokerage. The company aims to raise up to $5 million before costs, with potential oversubscriptions subject to ASX rules, and is distributing all offer documents and applications electronically via its share registry portal, with the offer closing on 24 February 2026.
The move underscores Actinogen’s continued reliance on retail shareholder support to strengthen its balance sheet and fund its operations, while also aligning with a broader market shift toward digital-only capital raisings to reduce printing and mailing costs. Existing investors who participate can increase their exposure at a set price within a defined window, while the electronic-only process may streamline administration but requires shareholders to engage online or request mailed copies and still complete payments via electronic channels.
The most recent analyst rating on (AU:ACW) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.
Actinogen Medical has launched a share purchase plan offering eligible shareholders in Australia and New Zealand, and a limited number of U.S. employees, the chance to buy up to $30,000 of new shares at $0.042 each without brokerage. The offer price matches a recent institutional placement and represents a discount to the last traded price and recent VWAP, with the company targeting up to $5 million in proceeds and reserving the right to scale back applications.
The share purchase plan follows firm commitments of about $12 million under a separate placement, of which roughly $11.3 million has already been raised, with the balance subject to shareholder approval. Funds from both the placement and the plan will be directed to completing the XanaMIA pivotal Alzheimer’s trial, implementing its open-label extension, providing working capital, and covering capital raising costs, potentially accelerating Actinogen’s clinical and operational progress in Alzheimer’s drug development.
The most recent analyst rating on (AU:ACW) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.
Actinogen Medical has raised capital by issuing 269,833,333 new fully paid ordinary shares at $0.042 each to sophisticated and institutional investors through an institutional placement. The company has confirmed it remains compliant with its continuous disclosure and financial reporting obligations, and that there is no excluded information that would affect the value of these newly issued shares.
The placement strengthens Actinogen’s balance sheet as it advances late-stage clinical programs for its lead drug Xanamem, including the XanaMIA Phase 2b/3 trial and an upcoming open-label extension in Alzheimer’s disease. Successful execution of these trials could enhance Actinogen’s position in the competitive neurodegenerative and neuropsychiatric treatment landscape, with potential implications for long-term shareholder value and future partnering or commercialization opportunities.
The most recent analyst rating on (AU:ACW) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.
Actinogen Medical has applied to the ASX for quotation of 269,833,333 new fully paid ordinary shares under code ACW, with an issue date of 9 February 2026. The substantial new share quotation reflects a significant capital move that may impact the company’s share structure and liquidity, potentially influencing investor interest and the funding of its ongoing medical development programs.
The most recent analyst rating on (AU:ACW) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.
Actinogen Medical has applied for quotation on the ASX of 190,228 new ordinary fully paid shares, following the exercise or conversion of existing options or other convertible securities. The additional securities, to be quoted from 5 February 2026, represent a modest increase in the company’s listed capital base and may marginally enhance liquidity for shareholders without signaling any broader operational or strategic shift disclosed in the filing.
The most recent analyst rating on (AU:ACW) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.
Actinogen Medical has announced a proposed issue of up to 119,047,619 new ordinary fully paid shares under a securities purchase plan, with a record date of 30 January 2026, an offer closing date of 24 February 2026, and an issue date of 2 March 2026. The capital raising via the share purchase plan is intended to broaden shareholder participation and strengthen the company’s balance sheet, which may support ongoing clinical development activities and enhance its financial flexibility in the competitive biotech sector.
The most recent analyst rating on (AU:ACW) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.
Actinogen Medical has notified the ASX of a proposed placement or similar issue of up to 15,880,953 new ordinary fully paid shares, with a planned issue date of 18 March 2026. The move signals the company’s intention to raise additional equity capital, which may be used to support its ongoing operations and strategic initiatives, and could lead to share dilution for existing investors while potentially strengthening its balance sheet and funding capacity.
The most recent analyst rating on (AU:ACW) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.
Actinogen Medical Limited has announced a proposed placement of up to 269,833,333 ordinary fully paid shares, with an expected issue date of 9 February 2026. The capital raising, conducted via a placement structure, is intended to expand the company’s securities on issue and may strengthen its balance sheet and funding capacity, with potential implications for existing shareholders through increased dilution and for the company’s ability to pursue its development and commercial objectives.
The most recent analyst rating on (AU:ACW) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.
Actinogen Medical has secured firm commitments for a share placement of approximately A$12 million at A$0.042 per share, issuing about 285.7 million new shares, with directors including CEO Dr Steven Gourlay committing around A$667,000 subject to shareholder approval. The funds, alongside up to A$5 million to be sought via a share purchase plan for eligible shareholders on the same terms, extend the company’s funding beyond the expected November 2026 topline results of its XanaMIA pivotal Alzheimer’s trial, de‑risking the program’s near-term development, broadening institutional and retail investor participation, and supporting the open-label extension and general corporate purposes.
The most recent analyst rating on (AU:ACW) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.
Actinogen Medical reported that its pivotal XanaMIA phase 2b/3 Alzheimer’s disease trial has successfully randomized 247 participants—above the original target—and that an independent Data Monitoring Committee has recommended the study continue unchanged following an interim analysis of unblinded safety and efficacy data, with topline results expected in November 2026. The company is also set to launch an open-label extension phase this quarter to provide up to 25 months of Xanamem treatment and long-term safety and efficacy data, while in parallel advancing manufacturing, commercial planning, partnering discussions, and additional patent filings, underscoring its transition into late-stage development and its bid to secure a competitive foothold in the fast-evolving Alzheimer’s therapeutics landscape.
The most recent analyst rating on (AU:ACW) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.
Actinogen Medical has requested a continuation of its trading halt on the ASX as it considers a proposed material capital raising, following a positive recommendation from its Data Monitoring processes. The halt, approved by the exchange, will remain in place until the company releases further details on the funding or trading resumes on 2 February 2026, signalling a potentially significant financing event to support its late-stage clinical programs and broader development of Xanamem in Alzheimer’s and related neurological conditions.
The most recent analyst rating on (AU:ACW) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.
Actinogen Medical has requested and been granted a trading halt in its securities on the ASX pending the release of results from an interim analysis of its XanaMIA Phase 2b/3 Alzheimer’s disease trial, conducted by an independent Data Monitoring Committee. The halt will remain in place until either the interim analysis outcome is announced to the market or trading resumes on 2 February 2026, signalling that pivotal clinical data may be imminent and potentially significant for the company’s development trajectory and investor sentiment.
The most recent analyst rating on (AU:ACW) stock is a Hold with a A$0.05 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.
Actinogen Medical has secured a second, non-dilutive tranche of $4.3 million in research and development tax funding from Endpoints Capital, part of a previously announced facility of up to $13.8 million backed by the company’s forecast FY26 R&D Tax Incentive rebate. The fresh capital will support the ongoing XanaMIA Phase 2b/3 Alzheimer’s disease trial, which is now fully enrolled at 35 sites in Australia and the US, the launch of its open-label extension in the current quarter, and general working capital, bolstering Actinogen’s balance sheet and extending its cash runway to mid-2026 as it approaches an interim analysis and final topline results expected in November 2026.
The most recent analyst rating on (AU:ACW) stock is a Hold with a A$0.05 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.
Actinogen Medical Limited has applied for quotation on the ASX of 27,566 new fully paid ordinary shares, issued following the exercise or conversion of options or other convertible securities. While a relatively small allotment, the additional quoted shares modestly expand the company’s equity base and reflect ongoing capital management activity as Actinogen advances its operations and development programs, with implications for existing shareholders’ dilution and market liquidity.
The most recent analyst rating on (AU:ACW) stock is a Hold with a A$0.05 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.
Actinogen Medical Limited has applied to the ASX for quotation of 43,392 new ordinary fully paid shares, following the exercise or conversion of existing options or other convertible securities. The modest increase in quoted securities slightly expands the company’s share capital base, reflecting ongoing issuance under existing equity arrangements but without indicating any major change in its operational strategy or capital structure.
The most recent analyst rating on (AU:ACW) stock is a Hold with a A$0.05 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.
Actinogen Medical has dispatched four senior executives to San Francisco to meet investors, analysts and potential partners at the Sachs Neuroscience Innovation Forum and events around the J.P. Morgan Healthcare Conference, aiming to raise the company’s profile among key neuroscience-focused stakeholders. The meetings centre on the company’s Xanamem Alzheimer’s program, highlighting multiple supportive clinical trials and the advanced XanaMIA Phase 2b/3 study, which has completed recruitment and is on track to deliver an interim analysis in late January 2026 and final topline results in November 2026, a timeline that could be pivotal for Actinogen’s clinical and commercial positioning if the data are positive.
The most recent analyst rating on (AU:ACW) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.
Actinogen Medical has applied to the ASX for quotation of 4,695,960 new fully paid ordinary shares, to be issued on 8 January 2026 under the code ACW. The additional securities, arising from the exercise or conversion of existing options or other convertible instruments, modestly expand the company’s listed share base and may provide incremental funding flexibility and liquidity for shareholders as Actinogen progresses its development activities.
The most recent analyst rating on (AU:ACW) stock is a Buy with a A$0.08 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.
Actinogen Medical Limited has applied to the ASX for quotation of 82,093 new fully paid ordinary shares, to be issued on 2 January 2026 under the ticker ACW. The modest increase in quoted securities reflects the conversion or exercise of existing options or other convertible instruments, slightly expanding the company’s share base and providing incremental capital or aligning incentives for stakeholders, without indicating any major strategic shift in its operations.
The most recent analyst rating on (AU:ACW) stock is a Buy with a A$0.08 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.
Actinogen Medical Limited has applied to the ASX for quotation of 4,000,000 new ordinary fully paid shares, which are scheduled to be issued and commence trading on 23 December 2025 under the ticker ACW. The additional securities, arising from the exercise or conversion of existing options or other convertible instruments, modestly expand the company’s share base and may provide incremental capital and liquidity, with implications for existing shareholders through potential dilution and for the company’s financial flexibility as it advances its business activities.
The most recent analyst rating on (AU:ACW) stock is a Buy with a A$0.08 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.
Actinogen Medical Limited has applied to the ASX for quotation of 218,449 new ordinary fully paid shares, to be listed under its existing ticker ACW. The additional securities, issued on 19 December 2025 following the exercise or conversion of existing instruments, will modestly expand the company’s free float and may incrementally enhance liquidity for shareholders without indicating any broader strategic shift in operations.
The most recent analyst rating on (AU:ACW) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.
Actinogen Medical has completed participant enrollment for its XanaMIA phase 2b/3 clinical trial, aimed at evaluating its novel Alzheimer’s treatment, Xanamem. The trial enrolled 246 participants, exceeding the initial target, which enhances its statistical power. Data will be assessed through an interim analysis in early 2026, with topline results anticipated by November 2026. This milestone underscores the potential of Xanamem as a groundbreaking, once-daily oral therapy designed to control brain cortisol, with implications for Alzheimer’s patients and the broader neurotherapeutic market.
The most recent analyst rating on (AU:ACW) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.
Actinogen Medical Limited has announced the quotation of 101,001 fully paid ordinary securities on the Australian Securities Exchange (ASX) as of December 12, 2025. This move is part of the company’s strategic efforts to enhance its market presence and provide more liquidity for its shareholders, potentially impacting its operations and positioning within the biotechnology sector.
The most recent analyst rating on (AU:ACW) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.
Actinogen Medical Limited has announced the quotation of 251,050 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of December 5, 2025. This move marks a significant step for the company, potentially enhancing its market presence and providing additional capital for its operations, which could positively impact its stakeholders.
The most recent analyst rating on (AU:ACW) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.
Actinogen Medical Limited has announced the quotation of 1,078,721 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of December 1, 2025. This move is part of the company’s strategic efforts to enhance its capital structure and support ongoing research and development activities, potentially strengthening its position in the biotechnology sector.
The most recent analyst rating on (AU:ACW) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.